阿可替尼治疗B细胞淋巴瘤临床应用指导原则(2023年版)  

Guiding principles for clinical application of acalabrutinib in B-cell lymphoma

作　　者：中国临床肿瘤学会(CSCO)淋巴瘤专家委员会 马军[2] Lymphoma Expert Committee of Chinese Society of Clinical Oncology(CSCO);Ma Jun(不详;Harbin Institute of Hematology&Oncology,Harbin 150010)

机构地区：[1]不详 [2]哈尔滨血液病肿瘤研究所,哈尔滨150010

出　　处：《白血病．淋巴瘤》2023年第10期577-582,共6页Journal of Leukemia & Lymphoma

摘　　要：布鲁顿酪氨酸激酶(BTK)抑制剂作为小分子靶向药物, 目前被广泛用于血液肿瘤的治疗。阿可替尼是全球首款高选择性BTK抑制剂, 在2023年3月22日获得中国国家药品监督管理局附条件批准上市, 用于治疗既往至少接受过一种治疗的成年套细胞淋巴瘤患者。为进一步规范阿可替尼在血液肿瘤治疗中的临床应用, 专家组成员结合相关研究数据和指南推荐, 制定了阿可替尼临床应用指导原则, 供临床医生参考使用。As a small molecule targeted agent,Bruton tyrosine kinase(BTK)inhibitor has been widely used in treatment of hematologic malignancies.Acalabrutinib is the first highly selective BTK inhibitor globally,and approved by National Medical Products Administration on March 22th 2023 in the treatment of adult mantle cell lymphoma patients who received at least 1 therapy regimen.To standardize the clinical practice of acalabrutinib in hematologic malignancies in advance,the Chinese experts work out this clinical guidance by combining the clinical data of acalabrutinib and guidelines recommendation to provide references for clinical physicians.

关 键 词：血液肿瘤 Bruton酪氨酸激酶抑制剂 阿可替尼 

分 类 号：R969[医药卫生—药理学]